Phase 1 Evaluation of AB521 Monotherapy and Combination Therapies in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

The primary objective of this Phase 1 study is to evaluate the safety and tolerability of **AB521** as a monotherapy and in combination therapies in patients with **Clear Cell Renal Cell Carcinoma** and other **Solid Tumors**. This is clinically relevant as it aims to determine the potential of AB521 to provide a new therapeutic option for these conditions, which are often challenging to treat with existing therapies.

The clinical trial involves a total of **282 participants** diagnosed with **Clear Cell Renal Cell Carcinoma** or **Solid Tumors**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the efficacy and safety of AB521 as a monotherapy and in combination therapies for **Clear Cell Renal Cell Carcinoma** and other **Solid Tumors**. This is a Phase 3, randomized, double-blind, controlled study. The trial is expected to commence recruitment on April 30, 2025, and is estimated to conclude by June 13, 2027. Participants will be involved in the study for a duration that aligns with the trial's overall timeline, subject to individual response and tolerability.

The study will include several key visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. Regular follow-up visits will be scheduled to monitor the participants' health status, treatment response, and any adverse events. These visits are crucial for ensuring participant safety and collecting data on the primary and secondary endpoints of the study. The end-of-study visit will occur at the conclusion of the treatment period, where final assessments will be conducted to evaluate the overall outcomes of the trial.

Participant involvement is expected to last until the end of the study unless specific conditions necessitate early termination. Such conditions may include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed appropriate by the study investigators. The trial's design and procedures are structured to maintain scientific rigor while ensuring participant safety and data integrity throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on April 30, 2025, with an estimated completion date of June 13, 2027. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology for measuring, collecting, and analyzing these efficacy parameters, consistent with Phase 3 trial standards. The trial's design will ensure that data collection and analysis are conducted systematically to provide reliable and valid results. The absence of specific endpoints or measurement tools in the provided data suggests that these details will be defined in the full trial protocol, adhering to regulatory and scientific guidelines for Phase 3 trials.